| Trial registration number
|
NCT04622865 |
Full text link
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04622865
|
First author
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Clinical Study Coordinator
|
Contact
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
clinical@ab-science.com
|
Registration date
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
2020-11-10
|
Recruitment status
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Recruiting
|
Study design
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
multi-center
|
Study aim
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
- has laboratory-confirmed sars-cov-2 infection
- hospitalized patients for the treatment of covid pneumopathy
- patients not requiring icu at admission with moderate and severe pneumopathy according
to the oms criteria of severity of covid pneumopathy.
|
Exclusion criteria
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
None
|
Number of arms
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
AB Science
|
Inclusion age min
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
France
|
Type of patients
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Moderate/severe disease at enrollment
|
Severity scale
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
4: Moderate/severe disease at enrollment
|
Total sample size
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
200
|
primary outcome
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Clinical status of patients at day-15 using a 7-point ordinal scale
|
Notes
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov
|
Phase 2
|
Arms
Last imported at : Nov. 11, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 1621, "treatment_name": "Isoquercetin+masitinib", "treatment_type": "Others pharmacological treatment+antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
|